SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

Myriad Genetics (MYGN) announced that the United States Patent ... MRD methods that are performed via an automation system configured to interface with laboratory equipment. U.S. patent No. 12,215,392 ...

Myriad Genetics, Inc. has launched a new educational ... pregnant women between 7-37 weeks gestational age. In a 2021 laboratory test, SneakPeek accurately determined fetal sex in 99.02% of ...

Myriad is acknowledged as one of the first commercial laboratories to market a multi-ancestry breast-cancer PRS, supporting its commitment to health equity and inclusive genetic insights.

Myriad offers three genetic tests to those who are pregnant ... pregnant women between 7-37 weeks gestational age. In a 2021 laboratory test, SneakPeek accurately determined fetal sex in 99. ...

In a 2021 laboratory test, SneakPeek accurately determined fetal ... SneakPeek accurately determined fetal sex for 100% of 103 women at 6 weeks gestational age. Myriad Genetics is a leading genetic ...

Myriad offers three genetic tests to those who are pregnant or are considering ... in 99.9% of 1,029 pregnant women between 7-37 weeks gestational age. In a 2021 laboratory test, SneakPeek accurately ...

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...